Details for Patent: 8,586,586
✉ Email this page to a colleague
Title: | Methods and compositions for treating or preventing erythema |
Abstract: | Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one .alpha.-adrenergic receptor agonist and a pharmaceutically acceptable carrier. |
Inventor(s): | Graeber; Michael (Lawrenceville, NJ), Loesche; Christian (Valbonne, FR), Freidenreich; Philip (Yardley, PA), DeJovin; Jack A. (New Brunswick, NJ), DeJovin; Isabelle Jean (New Brunswick, NJ), Liu; Yin-sang (Princeton Junction, NJ), Leoni; Matthew James (Hampton, NJ) |
Assignee: | Galderma Laboratories Inc. (Fort Worth, TX) |
Filing Date: | Mar 08, 2013 |
Application Number: | 13/791,059 |
Claims: | 1. A method of treating erythema or a symptom associated therewith in a subject, the method comprising topically administering to a skin area of the subject a topical composition comprising about 0.01% to about 10% by weight of at least one alpha adrenergic receptor agonist and a pharmaceutically acceptable carrier, wherein the skin area is, or is prone to be, affected by the erythema or the symptom associated therewith. 2. The method of claim 1, wherein the topical composition is selected from the group consisting of an aqueous solution topical formulation, cream topical formulation, and ointment formulation. 3. The method of claim 1, wherein the erythema is erythema of rosacea. 4. The method of claim 1, wherein the at least one alpha-adrenergic receptor agonist is an agonist selective for an alpha 1-adrenergic receptor. 5. The method of claim 1, wherein the at least one alpha-adrenergic receptor agonist is an agonist selective for an alpha 2-adrenergic receptor. 6. The method of claim 1, wherein the at least one alpha-adrenergic receptor agonist is a non-selective alpha-adrenergic receptor agonist. 7. The method of claim 1, wherein the at least one alpha-adrenergic receptor agonist is brimonidine. 8. The method of claim 1, wherein the at least one alpha-adrenergic receptor agonist is oxymetazoline. 9. The method of claim 1, wherein the at least one alpha-adrenergic receptor agonist is naphazoline. 10. The method of claim 1, wherein the at least one alpha-adrenergic receptor agonist is selected from the group consisting of tetrahydrozoline, xylometazoline, phenylephrine, methoxamine, mephentermine, metaraminol, midodrine, epinephrine and norepinephrine. 11. The method of claim 1, further comprising administering to the subject at least one additional treatment and medication for erythema or the symptom associated therewith. 12. The method of claim 1, wherein the topical composition is administered to the skin area once daily. 13. The method of claim 1, wherein the topical composition comprises about 0.1% to 3% by weight of the at least one alpha adrenergic receptor agonist. 14. The method of claim 1, wherein the topical composition comprises about 0.05%-1% by weight of the at least one alpha adrenergic receptor agonist. |